[{"address1": "855 North Wolfe Street", "address2": "Suite 601", "city": "Baltimore", "state": "MD", "zip": "21205", "country": "United States", "phone": "737-289-0835", "website": "https://mirapharmaceuticals.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Erez  Aminov", "age": 44, "title": "CEO & Chairman", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Yanez M.B.A.", "age": 51, "title": "CFO, Secretary & Treasurer", "yearBorn": 1972, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Itzchak  Angel Ph.D.", "title": "Chief Scientific Advisor", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.102, "dayLow": 1.05, "dayHigh": 1.12, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.102, "regularMarketDayLow": 1.05, "regularMarketDayHigh": 1.12, "forwardPE": -2.0769231, "volume": 45942, "regularMarketVolume": 45942, "averageVolume": 723556, "averageVolume10days": 141120, "averageDailyVolume10Day": 141120, "marketCap": 15963373, "fiftyTwoWeekLow": 0.79, "fiftyTwoWeekHigh": 6.95, "fiftyDayAverage": 1.09108, "twoHundredDayAverage": 2.6143987, "currency": "USD", "enterpriseValue": 10499500, "floatShares": 7056838, "sharesOutstanding": 14780900, "sharesShort": 249165, "sharesShortPriorMonth": 107265, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.016900001, "heldPercentInsiders": 0.56065, "heldPercentInstitutions": 0.00719, "shortRatio": 0.15, "shortPercentOfFloat": 0.0225, "impliedSharesOutstanding": 15338700, "bookValue": 0.549, "priceToBook": 1.9672132, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -7544444, "trailingEps": -0.51, "forwardEps": -0.52, "52WeekChange": -0.8286604, "SandP52WeekChange": 0.28136122, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MIRA", "underlyingSymbol": "MIRA", "shortName": "MIRA Pharmaceuticals, Inc.", "longName": "MIRA Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1692019800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a71f8b50-3996-3ccd-98e2-c993481fee2f", "messageBoardId": "finmb_1793899557", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.08, "targetHighPrice": 22.7, "targetLowPrice": 22.7, "targetMeanPrice": 22.7, "targetMedianPrice": 22.7, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 5868330, "totalCashPerShare": 0.397, "totalDebt": 108856, "quickRatio": 6.758, "currentRatio": 6.991, "debtToEquity": 1.341, "operatingCashflow": -4472824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]